J&J agrees $20.4 mn payment in Ohio opioid case

Johnson & Johnson agreed a $20.4 million settlement over allegedly fueling the opioid addiction crisis in Ohio
Johnson & Johnson agreed a $20.4 million settlement over allegedly fueling the opioid addiction crisis in Ohio

US healthcare giant Johnson & Johnson on Tuesday announced it had reached a $20.4 million settlement to avoid a much-anticipated trial in Ohio for allegedly fueling the opioid addiction crisis.

Several drugmakers have agreed deals ahead of the trial, due to open this month, which is seen as a national test case for many billions of dollars in settlements.

Millions of Americans sunk into addiction after using potent opioid painkillers that companies churned out and doctors freely prescribed over the past two decades.

The Johnson & Johnson agreement was with two Ohio counties ravaged by the opioid crisis—Cuyahoga and Summit.

The "resolves all of the counties' claims with no admission of liability and removes the from the federal trial," Johnson & Johnson said in a statement.

The company added it wanted to avoid the "uncertainty of a trial" and said it continues "to seek meaningful progress in addressing the nation's opioid crisis."

In August, an Oklahoma judge ordered Johnson & Johnson to pay $572 million in damages for its role in fostering .

The company was accused of aggressive promotion of prescription painkillers and downplaying or hiding risk of addiction.

The US epidemic has caused hundreds of thousands of overdose deaths.

Thousands of lawsuits have been lodged by states, cities, towns and Native American tribes seeking money to pay for overwhelmed health and social systems, families unable to care for themselves, and babies born addicted to the drugs.


Explore further

J&J ordered to pay $572 million for opioid addiction crisis

© 2019 AFP

Citation: J&J agrees $20.4 mn payment in Ohio opioid case (2019, October 2) retrieved 9 December 2019 from https://medicalxpress.com/news/2019-10-jj-mn-payment-ohio-opioid.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments